Outcome of heparin-treated patients with acute cerebral venous sinus thrombosis: influence of the temporal pattern of intracerebral haemorrhage.
The influence of temporal patterns of intracerebral haemorrhage (ICH) on the outcome of heparin-treated patients with cerebral venous sinus thrombosis (CVST) has not been examined systematically.



Temporal patterns of ICH and their influence on survival without disability (modified Rankin Scale score ≤1 point) at hospital discharge were examined in 141 consecutive hospital-admitted patients with acute CVST who were treated with intravenous unfractionated heparin.



Of all 141 patients (median age 40 years; 73% women), 59 (42%) had ICH at the time of diagnosis (early ICH). Of these, seven (12%) subsequently had extension of ICH and 13 (22%) had additional ICHs at other locations (delayed ICH). Of 82 patients without early ICH, nine (11%) later had delayed ICH. After a median hospital stay of 26 days, 107 patients (76%) were discharged without disability. Patients with early ICH were less likely to survive without disability until discharge than those without early ICH [63% vs. 85%; risk ratio (RR) 0.73; P = 0.005]. The association was attenuated after adjusting for age, sex and impaired consciousness on admission (RR 0.83; P = 0.03). Taking temporal patterns of ICH into account, early ICH with subsequent complication (extension or delayed ICH) had a larger influence on survival without disability (RR 0.57; 95% confidence interval 0.35-0.95) than early ICH without complications (RR 0.78; 95% confidence interval 0.67-0.91).



Heparin-treated CVST patients were less likely to survive without disability when ICH was present on admission. This association may largely be driven by subsequent extension of haemorrhage or additionally occurring delayed haemorrhage.
Department of Epidemiology and Health Monitoring, Robert Koch Institute, Berlin, Germany.|Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
M A
MA
Busch
Department of Neurology, Alexianer St Josefs-Krankenhaus Potsdam-Sanssouci, Potsdam, Germany.|NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.
O
O
Hoffmann
Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
K M
KM
Einhäupl
Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.|Department of Neurology, Bundeswehrkrankenhaus Berlin, Berlin, Germany.
F
F
Masuhr
D000293:Adolescent; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D002543:Cerebral Hemorrhage / Q000000981:diagnostic imaging / Q000209:etiology / Q000503:physiopathology*; D004185:Disability Evaluation; D005260:Female; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D007902:Length of Stay; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012851:Sinus Thrombosis, Intracranial / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D016019:Survival Analysis; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014474:Unconsciousness / Q000209:etiology; D055815:Young Adult
D000925:Anticoagulants; D006493:Heparin
cerebral venous sinus thrombosis; heparin; intracranial haemorrhage; outcome